復星醫藥(02196.HK):旗下新型肺炎藥獲准在美國開展臨床試驗
復星醫藥(02196.HK)(600196.SH)公布,控股子公司復宏漢霖(02696.HK)旗下全資附屬Hengenix Biotech,Inc.收到美國食品藥品監督管理局(FDA)批准,旗下用於治療新型冠狀病毒肺炎的抗S1全人源單克隆中和抗體HLX70,可於美國開展一期臨床試驗。
該新藥基於復宏漢霖與三優生物醫藥及上海之江生物科技的《合作開發協議》進行研發,擬用於新型冠狀病毒肺炎、新型冠狀病毒引起的急性呼吸窘迫綜合症或多重器官衰竭治療。截至2020年8月,集團現階段針對該新藥累計未經審計研發投入約1,520萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.